HROW Harrow Health Inc.

Harrow to Present at Two Investor Conferences in December

Harrow to Present at Two Investor Conferences in December

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December:

BTIG 5th Annual Ophthalmology Day (Virtual)

Format: Fireside chat

Date/Time: Monday, December 1, 2025, at 8:30 AM EST

Piper Sandler 37th Annual Healthcare Conference (New York, NY)

Format: Fireside chat

Date/Time: Tuesday, December 2, 2025, at 3:00 PM EST

The fireside chat at Piper Sandler will be webcast live and can be found on the Event’s page on the . A replay will be available for approximately 90 days following the event.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit

Contacts:

Mike Biega

Vice President of Investor Relations and Communications        

        

617-913-8890



EN
24/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conferen...

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida. The presentation will be and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event. About HarrowHarrow, Inc. (Nasdaq: HROW) is a leading p...

 PRESS RELEASE

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE®...

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to support a planned Phase 3 clinical trial evaluating TRIESENCE (preservative-free triamcinolone acetonide injectable suspension) 40 mg/mL for the treatment of ...

 PRESS RELEASE

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Fina...

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Ca...

 PRESS RELEASE

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results Af...

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026 NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the...

 PRESS RELEASE

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic Therapies NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company’s commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations. PharmaPack kits expand access to F...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch